6/15/2010

Composition of R&D Committee as of 15 June 2010

ORION CORPORATION      STOCK EXCHANGE RELEASE  15 June  2010  AT 01.55 EET     

        


The Board of Directors of Orion Corporation has decided to complement the composition of the R&D Committee with Matti Kavetvuo and Heikki Westerlund as new members as of 15 June 2010.  Accordingly, all members of the Board of Directors belong to the R&D Committee.

 

Composition of the R&D Committee as of 15 June 2010:

 

Sirpa Jalkanen (Chairman)

Eero Karvonen

Matti Kavetvuo

Hannu Syrjänen

Heikki Westerlund

Jukka Ylppö

 

                                                                                                                                                                            

Orion Corporation

 

 

Timo Lappalainen            Olli Huotari

President and CEO         SVP, Corporate Functions

 

 

Contact person:

Olli Huotari, SVP, Corporate Functions, phone +358 50 966 3054

 

 

Publisher:

Orion Corporation

Communications

Orionintie 1A, FI-02200 Espoo

Homepage: www.orion.fi

 

 

Orion is an innovative European R&D-based pharmaceutical and diagnostic company with a special emphasis on developing medicinal treatments and diagnostic tests for global markets. Orion develops, manufactures and markets human and veterinary pharmaceuticals, active pharmaceutical ingredients and diagnostic tests. Orion's pharmaceutical R&D focuses on the following core therapy areas: central nervous system drugs, cancer and critical care drugs, and Easyhaler® pulmonary drugs.

 

The Group's net sales in 2009 amounted to EUR 772 million. The Company invested EUR 95 million in research and development. At the end of 2009, the Group had a total of 3,100 employees, of whom 2,500 worked in Finland and 600 in other European countries. Orion's A and B shares are listed on NASDAQ OMX Helsinki.